Buy & Sell Tenet Healthcare Corporation (THC) – Tenet Healthcare Corporation Price Today
Aura AI Summary
Key Stats
- $15.43BMarket Cap
- HealthSector
- -23.75%3M Drawdown
- $25.67BEnterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 11 daysTypical Hold Time
Tenet Healthcare Corporation (THC) is currently valued at a market capitalization of $15.43B, with an enterprise value of $25.67B. Over the past 52 weeks, Tenet Healthcare Corporation has traded between a low of $148.38 and a high of $244.8, highlighting its annual price range. Over the past three months, Tenet Healthcare Corporation has recorded a drawdown of -23.75%, reflecting recent price volatility. On average, investors hold Tenet Healthcare Corporation for approximately 11 days, indicating typical investor behavior on the platform.
About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Most Recent News
Global GLP-1 receptor agonist market to reach $95.3B by 2035, growing at 12.1% CAGR driven by diabetes and obesity demand.
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...

Lawsuit alleges Corcept Therapeutics hid FDA concerns about key drug approval risks
Kuehn Law is investigating Corcept Therapeutics for allegedly failing to disclose FDA concerns about the clinical development of relacorilant, a drug candidate for Cushing's syndrome. The lawsuit claims Corcept misled shareholders by promoting expect...

Investigation launched into Simulations Plus for possible false statements affecting investors.
The Schall Law Firm is investigating Simulations Plus, Inc. for potentially issuing false or misleading statements and failing to disclose important information to investors. This probe could impact shareholders who may have suffered losses due to th...
